Traders should anticipate near-term dilution risk and monitor for pricing relative to current market levels. Given recent insider selling and the size of the offering relative to market cap (~30% of current value), sentiment may remain under pressure unless proceeds are tied to value-accretive catalysts.
Price Chart
Executive Summary
Allogene Therapeutics announced a proposed public offering of $175 million in common stock, with underwriters granted a 30-day option to purchase up to an additional $26.25 million. The company intends to use net proceeds for general corporate purposes, including clinical trials, R&D, and administrative expenses.
Key Financial Metrics
Key Facts
- Allogene Therapeutics (ALLO) plans a public offering of $175 million in common stock.
- Underwriters have a 30-day option to purchase up to an additional $26.25 million in shares.
- Proceeds will fund general corporate purposes, including clinical trials, R&D, and capital expenditures.
- Goldman Sachs, Jefferies, and TD Cowen are joint book-running managers.
- Offering is subject to market conditions; no assurance the offering will be completed.
Financial Impact
Up to $201.25 million in gross proceeds if the overallotment is exercised.
Risk Factors
- Significant equity dilution for existing shareholders if the offering is completed near current levels.
- Uncertainty around timing and final terms of the offering, including potential discount to market price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272887 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.21 (−3.20%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.21 (−38.89%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.21 (−40.39%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.21 (+42.11%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.21 (−38.58%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.21 (−44.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers